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a Unit for Degradomics of the Protease Web, Institute of Biochemistry, University of Kiel, 24118 Kiel, Germany
b Institute for Pathobiochemistry, University Medical Center of the Johannes Gutenberg University of Mainz, 55128 Mainz, GermanyDue to the growing population of people at advanced age, the num-
ber of patients affected by Alzheimer's disease (AD) is increasing
tremendously. In 2015 about 46.8 million people suffered from AD
worldwide which is estimated to increase to 131.5 million by 2050.
Brains of AD patients all show a common histopathology; they are
marked by an atrophy and degeneration that is caused by a severe
loss of neurons and synapses (Braak and Del Tredici, 2012). Moreover,
so-called extracellular senile plaques that consist of predominantly am-
yloid β (Aβ) peptides can be detected in the grey matter where they
surround neurons. Since generation of Aβ peptides is hypothesized to
play a major role in AD pathogenesis, it is essential to decipher the en-
zymatic cascade leading to the generation of Aβ. Most of the Aβ-
peptides are initially generated by β-secretase (BACE1) with subse-
quent γ-secretase cleavage of the amyloid precursor protein (APP). In
contrast, ADAM10 as α-secretase cleaves APP within the Aβ sequence
and prevents the generation and subsequent accumulation of this neu-
rotoxic peptide. Recently, several studies described the presence of N-
terminally truncated Aβ peptides in brain or cerebrospinal ﬂuid (CSF),
including Aβ2–42, pyroglutamate Aβ3–42 (AβpE3–42) or Aβ4–42
(Kummer andHeneka, 2014). However, BACE-1 is incapable in generat-
ing these truncated peptides, since it only cleaves APP in amino acid po-
sitions p1 or p11 of theAβ peptide (Vassar et al., 1999). Therefore, it is of
utmost importance to identify new players in APP metabolism that
might have been overlooked so far, possibly due to low expression,
lack of appropriate tools, or other experimental confounds.
A striking challenge in studying Alzheimer's disease is the use of ap-
propriate animal models. Since Aβ peptides derived from murine APP
do not lead to neurodegeneration, almost all animal studies are based
on humanized mice overexpressing human APP. Moreover, the mutated
APP variant inserted in these animals is almost exclusively cleaved N-
terminally by BACE-1 lacking the generation of N-terminally truncated
Aβ peptides. Although, these animal models are of great value, they
may exhibit critical restrictions: potential factors involved in pathological
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like meprin βmay be involved in the generation of N-terminal truncated
Aβ peptides, but the in vivo relevance remains unclear due to the lack of
mousemodels (Schonherr et al., 2016). In this issue of EBioMedicine, Lam-
bert and colleagues report on themetalloprotease ADAM30 as a potential
regulator of APPprocessing,which itself is also not expressed under phys-
iological conditions in mice (Letronne et al., 2016).
Most interestingly, ADAM30was found tobe expressed at lower levels
in brains of AD patients compared to controls and the authors demon-
strate correlation of low expression of ADAM30with increased Aβ levels.
Thus, ADAM30 does not act like the α-secretase ADAM10, but instead
ADAM30was found to induce cathepsinDactivity through itsmaturation,
subsequently inﬂuencing lysosomal APP metabolism. Remarkably, both
enzymes were identiﬁed in unbiased screens, ADAM30 in a GWAS
study and cathepsin D with the help of modern proteomics techniques
for the identiﬁcation of protease substrates of ADAM30. The activation
of cathepsinDbyADAM30wasunexpected, andbrings back an old player
into the game.More than twenty years ago cathepsin Dwas implicated in
Alzheimer's disease (Cataldo et al., 1995; Ladror et al., 1994). However,
themurine knock-out of the cathepsin D gene had no effect on Aβ forma-
tion (Saftig et al., 1996). Interestingly it had been demonstrated that ca-
thepsin D displays BACE 1-like β-secretase speciﬁcity at low pH values
but shows poor kinetic activity towards the wildtype β-secretase amino
acid sequence (Schechter and Ziv, 2008).
Lambert and colleagues demonstrated that overexpression of
ADAM30 in transgenic mice led to reduced levels of Aβ42 due to in-
creased lysosomal APP cleavage by cathepsin D. Here, one might argue
that this is not a direct proof for the correlation of low ADAM30 expres-
sion in Alzheimer's disease patients and the onset and/or progression of
the disease. This is indeed true. However, it again demonstrates poten-
tial pitfalls using mouse models for AD, because ADAM30 is obviously
not expressed in the murine brain under physiological conditions,
which excludes the use of ADAM30 knock-out mice.
Therefore, it is important to combine different approaches to gain a
better understanding ofmolecular factors involved in the onset and pro-
gression of Alzheimer's disease. Murine models have great value but
certain drawbacks, which demonstrate the necessity of developing
new techniques better resembling the human system. For instance, a re-
cent paper reports on the employment of brain region speciﬁc organoid
cultures derived from human induced pluripotent stem cells (iPSCs)-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
20 C. Becker-Pauly, C.U. Pietrzik / EBioMedicine 9 (2016) 19–20(Qian et al., 2016). This platformwas used tomodel Zika virus exposure
but it may also be a suitable approach to study Aβmediated neurode-
generation in a human system.
Dementia is a global threat and to date no effective treatment for AD
is available more than 100 years after the discovery of the disease
by Alois Alzheimer. Hence, the key message from the paper is: Keep
one's eyes peeled for yet ambiguous factors potentially involved in
Alzheimer's disease. Theymay oneday lead to biomarkers or treatments
for this devastating disease.
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